Peter the Bridge, Saint Petersburg, Russia

NEOMED and Mitacs Announce First Partnership Project

October 2nd, 2014 | No Comments

NEOMED, a not-for-profit organization whose mission is to serve as a bridge between academic research and the pharmaceutical industry, along with Mitacs, an organization developing the next generation of innovators in Canada, are announcing the selection and launch of the first project in their strategic partnership.

The selected project is from the laboratory of Dr. Donald Poirier, researcher at the Centre de recherche du CHU de Québec and professor at the Université Laval’s Faculty of Medicine. It focuses on identifying a new anti-cancer candidate molecule in the aminosteroid family for development as a potential drug.


“There is a tremendous need to discover new drugs that are more effective against cancer cells, while not affecting healthy cells,” said Dr. Philippe Walker, Chief Scientific Officer at NEOMED. “That’s why we find Dr. Poirier’s approach very appealing and promising. We’d like to explore with him the potential of finding a new way to treat cancer and continue with this project if the results are positive,” he added.


“We’re going to single out a new candidate molecule from the aminosteroid family and test its action on two treatment-resistant (refractory) cancers, such as ovarian and pancreatic cancer. The preliminary results are very encouraging because they suggest that this group of compounds attacks cancer cells exclusively and spares healthy cells. NEOMED and Mitacs’ support is very important at this stage. It will help us better understand these candidate molecules’ mechanisms of action and define more clearly the therapeutic target involved,” stated Dr. Poirier.


“We’re very happy to see that Dr. Poirier’s project works in an area that is so important to the public and that the proposal will enable a quick assessment of the potential of these new therapeutic molecules,” said Jesse Vincent-Herscovici, Senior Account Manager at Mitacs. “Our partnership with NEOMED helps fund research projects that are still in the early stages of development. We are able to add value by assigning postdocs, which enables the partner to make significant progress.”


Dr. Poirier’s project is part of the program put in place by NEOMED and Mitacs to fund the evolution of projects for the development of drugs with a strong potential that could in the future enhance NEOMED’s portfolio. The two organizations encourage research teams in Quebec to submit their ideas and project proposals for drug development.


– 30 –




NEOMED is a not-for-profit organization whose mission is to foster the development of promising therapeutic approaches emerging from academia and biotechnology companies. NEOMED supports the development of projects up to the stage of human proof of concept. NEOMED is jointly funded by the pharmaceutical industry, the Ministère de l’Économie, de l’Innovation et des Exportations du Québec, and the Networks of Centres of Excellence (NCE) of Canada.


NEOMED operates within the NEOMED Institute, a high-tech research and development centre located at Technoparc Montréal’s Saint-Laurent Campus. NEOMED Institute acts as an open-access drug discovery hub, housing commercial companies and offering a unique environment to nurture collaboration, innovation, and creativity.


For more information, please visit our website:



Mitacs is a national, not-for-profit organization that develops the next generation of innovators with vital skills through a suite of unique research and training programs: Mitacs Accelerate, Elevate, Step, and Globalink. In partnership with private companies, government and universities, Mitacs is supporting a new economy using Canada’s most valuable resource — its people.


For more information, please contact:

Mounia Azzi, Ph.D.
Director, Scientific Affairs


7171 Frederick-Banting
Montréal (Québec) H4S 1Z9




Heather Young
Director, Communications




Download the PDF

Share this

Similar News

image articles
10 April 2018

NEOMED Therapeutics 1 names Dr. Frank Giles as Chief Medical Officer

Read complete news
image articles
28 February 2018

NEOMED Institute Launches NEOMED Therapeutics 1 Inc. to fund and develop a dual BET inhibitor anticancer therapy pipeline with NEO2734, an oral dual BET and CBP/P300 inhibitor, as lead compound

Read complete news
© 2018 NEOMED Institute. All Rights Reserved. // Solutions Web Globalia